Healthier Together and philanthropic ventures in tropical disease
Europe launches the EU Non-communicable diseases (NCDs) initiative, while GSK and Novartis promise millions to support drug R&D for neglected tropical diseases and malaria.
List view / Grid view
News
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323649599-300x278.jpg)
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323657672.jpg)
Alexion to expand biologics manufacturing with €65m investment
The investment in new drug substance production equipment and warehousing facilities to enhance Alexion’s biologics manufacturing in Ireland.
BioNTech launches African vaccine production in Rwanda
Marking the initiation of its African vaccine manufacturing network, BioNTech begins construction of its hub site in Rwanda.
Greece slaps Novartis with €214 million bribery suit
The Greek state is seeking millions in compensation for non-economic damages that may have resulted from Novartis allegedly bribing both government officials and doctors.
Topline results show eplontersen slows disease progression in polyneuropathy patients
Data in the NEURO-TTRansform study demonstrates that eplontersen had a positive impact on disease progression, including improvement in neuropathy impairment and quality of life in a substantial number of patients.
Moderna announces UK mRNA Innovation and Technology Centre
Moderna to establish a UK mRNA Innovation and Technology Centre to produce mRNA vaccines for COVID-19, influenza, respiratory syncytial virus (RSV) and more.
AEX-MS to become increasingly important in antibody characterisation
Study shows AEX-MS enables the analysis of IgG4 Fc deamidation variants and, as IgG4 antibodies become more popular, could become increasingly valuable for antibody charge heterogeneity characterisation.
Improved outcome for prostate cancer patients in Phase III PROpel trial
Lynparza (Olaparib) in combination with abiraterone plus prednisone reduced the risk of disease progression or death by 34 percent in the Phase III PROpel trial for prostate cancer patients.
New microencapsulation approach allows slow release of peptide drugs
A study from the University of Michigan shows a new method of drug microencapsulation, allowing several peptide drugs to be slowly released in the body.
Relugolix meaningfully reduces endometriosis pain
The Phase III trials saw 75 percent of women in the relugolix combination therapy group achieve a reduction in dysmenorrhea (menstrual pain), compared with 30 percent or less of women in the placebo groups.
Heparin affinity chromatography promising for extracellular vesicle purification
Researchers find that heparin affinity chromatography (HAC) produces highly pure extracellular vesicles with greater recovery than existing purification methods.
Final positive results of Zolgensma® trial for SMA published
After previous reports that nearly all spinal muscular atrophy (SMA) patients treated with Zolgensma® achieved key motor milestones, Novartis announces publication of full SPR1NT results.
Machine learning model enables adventitious agent detection in cell cultures
Researchers have developed a rapid, label-free process analytical technology, called the anomaly detection model, to monitor microbial contamination in cell cultures in near-real-time.
Highs and lows of DEI representation in the biotech industry
BIO International Convention 2022 shared the latest insights into diversity, equity and inclusion (DEI) in the biotechnology industry this week.
WTO waives intellectual property rights for COVID-19 vaccines
According to IFPMA, the World Trade Organization decision to waive intellectual property rights for COVID-19 vaccines fails to tackle the biggest barrier to access: trade.
